However, several biological mechanisms and clinical observations warrant consideration
By monitoring Loss of Exclusivity (LOE) forecasts and performing white space analysis, facilities can identify therapeutic areas with high demand but low patent density, or identify when specific formulation patents expire, allowing for the legal production of non-infringing compounds
Meanwhile, lower-income households, often located in regions with the highest obesity rates, face costs that place GLP-1s still firmly out of reach
Public-health and research sources also note that some people use kratom in an attempt to manage pain, substance dependence, or mental health problems, even though no kratom product is approved for those purposes in the United States
The overall risk is low, probably around 1% to 2%